KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Equity Average (2016 - 2025)

Pacira BioSciences has reported Equity Average over the past 15 years, most recently at $710.2 million for Q4 2025.

  • Quarterly results put Equity Average at $710.2 million for Q4 2025, down 7.04% from a year ago — trailing twelve months through Dec 2025 was $710.2 million (down 7.04% YoY), and the annual figure for FY2025 was $735.7 million, down 10.74%.
  • Equity Average for Q4 2025 was $710.2 million at Pacira BioSciences, down from $742.5 million in the prior quarter.
  • Over the last five years, Equity Average for PCRX hit a ceiling of $885.7 million in Q2 2024 and a floor of $635.3 million in Q1 2021.
  • Median Equity Average over the past 5 years was $767.7 million (2023), compared with a mean of $765.8 million.
  • Biggest five-year swings in Equity Average: surged 75.55% in 2021 and later decreased 12.14% in 2025.
  • Pacira BioSciences' Equity Average stood at $724.5 million in 2021, then rose by 6.63% to $772.6 million in 2022, then rose by 10.13% to $850.8 million in 2023, then fell by 10.21% to $764.0 million in 2024, then decreased by 7.04% to $710.2 million in 2025.
  • The last three reported values for Equity Average were $710.2 million (Q4 2025), $742.5 million (Q3 2025), and $778.2 million (Q2 2025) per Business Quant data.